title: Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
abstract: The recent studies have evaluated the relationship between BRCA1 expression and clinical outcome of chemotherapy (mainly focused on platinum-based and toxal-based treatment) in NSCLC patients, but the results were inconclusive and controversial. Our aim of this study was to evaluate this association by literature based system review and meta-analysis.PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases were used to retrieve the relevant articles. The interested outcome included objective response rate (ORR), overall survival (OS) and event-free survival (EFS). The pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) ware estimated.After specific inclusion and exclusion criteria, 23 studies fulfilled the criteria and were included in our analysis. In 17 platinum-based studies, low/negative BRCA1 was in favor of better ORR (OR=1.70, 95%CI=1.32-2.18), longer OS and EFS (HR=1.58, 95%CI=1.27-1.97, and HR=1.60, 95%CI=1.07-2.39 for OS and EFS, respectively). In 4 toxal-based chemotherapy studies, the patients with high/positive BRCA1 had better ORR (OR=0.41, 95%CI=0.26-0.64), OS and EFS were not evaluated as the insufficient data available.Overall, BRCA1 might be a useful biomarker to predict clinical outcome for personal chemotherapy in NSCLC patients in the future.
authors.affiliation: Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, China. Xianlei59@163.com.
authors.forename: Yanlong
authors.initials: Y
authors.lastname: Yang
authors.forename: Yuanliang
authors.initials: Y
authors.lastname: Xie
authors.forename: Lei
authors.initials: L
authors.lastname: Xian
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D017239:Paclitaxel